BioTime Provides Update on ReneviaTM Product Development; Product Development on Track for CE Marking by 2013
BioTime, Inc. (NYSE: BTX) announced today that William Tew, Ph.D., BioTime's Chief Commercial Officer will provide an update on the development of ReneviaTM (formerly known as HyStem®-Rx) at an investor meeting in New York City. In his presentation, Dr. Tew will discuss the global distribution network marketing the HyStem® line of research products being utilized in a wide array of medical research applications. Dr. Tew will also describe preclinical work underway at medical institutions throughout the United States including Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Harvard Medical School, and the University of Florida. Finally, Dr.
Tew will discuss the product development milestones for the launch of ReneviaTM in Europe, with the goal of obtaining the CE mark necessary for marketing ReneviaTM in European Union countries by year-end 2013. Dr. Tew's presentation and a video showing the potential use of the product in reconstructive surgery will be available for viewing on BioTime's web site www.biotimeinc.com.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.